DIAMOND BIOFUND Business Summary

Diamond Biofund (6901.TW) operates as Taiwan’s first publicly listed evergreen venture capital firm, specializing in the life sciences and healthcare sectors. Its business model is centered on generating long-term capital appreciation and dividend income through a "cradle-to-IPO" incubation strategy, focusing on four primary segments: new drug research and development, high-end medical devices, innovative medical services, and agricultural biotechnology. Unlike traditional private equity funds with fixed lifespans, Diamond’s evergreen structure allows it to support the extended R&D cycles inherent in biotech without the pressure of forced exits. In the competitive landscape, the firm occupies a unique niche as a pure-play listed investment vehicle, distinguishing itself from institutional venture arms like CDIB Capital Group, Cathay Venture, Fubon Financial Holding Venture Capital, and Taishin Venture Capital by offering retail and institutional investors direct liquid exposure to a diversified biotech portfolio. The company’s leadership is characterized by a high-pedigree blend of academic excellence and financial expertise, currently led by Chairman Pan-Chyr Yang, a renowned physician-scientist and former President of National Taiwan University. The executive team includes Vice Chairman Tsu-Der Lee, a veteran in international fund management, and President (CEO) Yolanda Wu, who brings a background in financial regulation and corporate finance. Diamond Biofund was founded in 2013 through a landmark alliance of Taiwan’s most influential industrial and financial titans, including the Microbio Group, Fubon Financial (led by the Tsai family), Taishin Holdings (Thomas Wu), and the Ruentex Group (Samuel Yin). The board’s governance is further strengthened by a high ratio of independent directors and representatives from its founding conglomerates, ensuring a robust scientific and financial vetting process for its global investment pipeline.